Chronic Hepatitis B Virus: What an Internist Needs to Know

References

1. • Polaris Observatory Collaborators
   Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.
   Lancet Gastroenterol Hepatol. 2018; 3: 383-403
   View in Article

   • Google Scholar
2. • Lok A.S.F.
   • McMahon B.J.
   Chronic hepatitis B.
   Hepatology. 2007; 45: 507-539
   View in Article

   • Google Scholar
3. • Le M.H.
   • Yeo Y.H.
   • Cheung R.
   • et al.
   Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999-2016.
   Hepatology. 2020; 71: 431-443
   View in Article

   • Google Scholar
4. • Xu J.J.
   • Tien C.
   • Chang M.
   • et al.
   Demographic and serological characteristics of Asian Americans with hepatitis B infection diagnosed at community screenings.
   J Viral Hepat. 2013; 20: 575-581
   View in Article

   • Google Scholar
5. • Hu K.Q.
   • Pan C.Q.
   • Goodwin D.
   Barriers to screening for hepatitis B virus infection in Asian Americans.
   Dig Dis Sci. 2011; 56: 3163-3171
   View in Article

   • Google Scholar
6. • Hyun S.
   • Ko O.
   • Kim S.
   • et al.
   Sociocultural barriers to hepatitis B health literacy in an immigrant population: a focus group study in Korean Americans.
   BMC Public Health. 2021; 21: 404
   View in Article

   • Google Scholar
7. • Kallman J.B.
   • Arsalla A.
   • Park V.
   • et al.
   Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians.
   Aliment Pharmacol Ther. 2009; 29: 1019-1024
   View in Article

   • Google Scholar
8. • Foster T.
   • Hon H.
   • Kanwal F.
   • et al.
   Screening high risk individuals for hepatitis B: physician knowledge, attitudes, and beliefs.
   Dig Dis Sci. 2011; 56: 3471-3487
   View in Article

   • Google Scholar
9. • Ku K.C.
   • Li J.
   • Ha N.B.
   • et al.
   Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics.
   Dig Dis Sci. 2013; 58: 3626-3633
   View in Article

   • Google Scholar
10. • Nguyen N.H.
    • Nguyen V.
    • Trinh H.N.
    • et al.
    Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy.
    Clin Gastroenterol Hepatol. 2013; 11: 565-571
    View in Article

    • Google Scholar
11. • Zhang S.
    • Ristau J.T.
    • Trinh H.N.
    • et al.
    Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study.
    Dig Dis Sci. 2012; 57: 1373-1383
    View in Article

    • Google Scholar
12. • Kim L.H.
    • Nguyen V.G.
    • Trinh H.N.
    • et al.
    Low treatment rates in patients meeting guideline criteria in diverse practice settings.
    Dig Dis Sci. 2014; 59: 2091-2099
    View in Article

    • Google Scholar
13. • Terrault N.A.
    • Bzowej N.H.
    • Chang K.M.
    • et al.
    AASLD guidelines for treatment of chronic hepatitis B.
    Hepatology. 2016; 63: 261-283
    View in Article

    • Google Scholar
14. • European Association for the Study of the Liver
    EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.
    J Hepatol. 2017; 67: 370-398
    View in Article

    • Google Scholar
15. • Sarin S.K.
    • Kumar M.
    • Lau G.K.
    • et al.
    Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
    Hepatol Int. 2016; 10: 1-98
    View in Article

    • Google Scholar
16. • Nguyen M.H.
    • Wong G.
    • Gane E.
    • et al.
    Hepatitis B virus: advances in prevention, diagnosis, and therapy.
    Clin Microbiol Rev. 2020; 33: 000466-19
    View in Article

    • Google Scholar
17. • Goodman Z.D.
    Grading and staging systems for inflammation and fibrosis in chronic liver diseases.
    J Hepatol. 2007; 47: 598-607
    View in Article

    • Google Scholar
18. • Amarapurkar D.
    • Amarapurkar A.
    Indications of liver biopsy in the era of noninvasive assessment of liver fibrosis.
    J Clin Exp Hepatol. 2015; 5: 314-319
    View in Article

    • Google Scholar
19. • Wong G.L.H.
    Update of liver fibrosis and steatosis with transient elastography (Fibroscan).
    Gastroenterol Rep (Oxf). 2013; 1: 19-26
    View in Article

    • Google Scholar
20. • Barr G.
    • Ferraioli G.
    • Palmeri M.
    • et al.
    Elastography assessment of liver fibrosis: society of radiologists in ultrasound consensus conference statement.
    Ultrasound Q. 2016; 32: 94-107
    View in Article

    • Google Scholar
21. • Lim J.K.
    • Flamm S.L.
    • Singh S.
    • et al.
    Clinical guidelines committee of the american gastroenterological association. american gastroenterological association institute guideline on the role of elastography in the evaluation of liver fibrosis.
    Gastroenterology. 2017; 152: 1536-1543
    View in Article

    • Google Scholar
22. • EASL-ALEH Clinical Practice Guidelines
    Non-invasive tests for evaluation of liver disease severity and prognosis.
    J Hepatol. 2015; 63: 237-264
    View in Article

    • Google Scholar
23. • Terrault N.A.
    • Lok A.S.F.
    • McMahon B.J.
    • et al.
    Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
    Hepatology. 2018; 67: 1560-1599
    View in Article

    • Google Scholar
24. • Krist A.H.
    • Davidson K.W.
    • Barry M.J.
    • et al.
    • US Preventive Services Task Force
    Screening for hepatitis B virus infection in adolescents and adults: US preventive services task force recommendation statement.
    JAMA. 2020; 324: 2415-2422
    View in Article

    • Google Scholar
25. Centers for Disease Control and Prevention. Federal register notice #CDC-2022-07050 for Hepatitis B screening and testing.
    (Available at:)
    https://www.cdc.gov/hepatitis/policy/isireview/HepBFederalRegisterNotice.htm

    Date: 2022
    (Accessed November 30, 2022)
    View in Article

    • Google Scholar
26. • Fung J.
    • Lai C.L.
    • Seto W.K.
    • et al.
    Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.
    J Antimicrob Chemother. 2011; 66: 2715-2725
    View in Article

    • Google Scholar
27. • Lok A.S.F.
    • McMahon B.J.
    • Brown Jr., R.S.
    • et al.
    Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.
    Hepatology. 2016; 63: 284-306
    View in Article

    • Google Scholar
28. • Jang J.W.
    • Choi J.Y.
    • Kim Y.S.
    • et al.
    Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis.
    Hepatology. 2015; 61: 1809-1820
    View in Article

    • Google Scholar
29. • Chien R.N.
    • Yeh C.T.
    • Tsai S.L.
    • et al.
    Determinants for sustained HBeAg response to lamivudine therapy.
    Hepatology. 2003; 38: 1267-1273
    View in Article

    • Google Scholar
30. • Fattovich G.
    • Stroffolini T.
    • Zagni I.
    • et al.
    Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
    Gastroenterology. 2004; 127: S35-S50
    View in Article

    • Google Scholar
31. • Chen C.J.
    • Yang H.I.
    • Su J.
    • et al.
    Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
    JAMA. 2006; 295: 65-73
    View in Article

    • Google Scholar
32. • Lok A.
    Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?.
    J Gastroenterol Hepatol. 2011; 26: 221-227
    View in Article

    • Google Scholar
33. • Yu M.
    • Lin C.
    • Lin C.
    • et al.
    Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study.
    Gastroenterology. 2017; 153: 1006-1017.e5
    View in Article

    • Google Scholar
34. • Chan A.
    • Wong G.
    • Chan H.
    • et al.
    Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.
    J Gastroenterol Hepatol. 2017; 32: 667-676
    View in Article

    • Google Scholar
35. • Huang Y.
    • Yang H.
    • Liu J.
    • et al.
    Mediation analysis of hepatitis B and C in relation to hepatocellular carcinoma risk.
    Epidemiology. 2016; 27: 14-20
    View in Article

    • Google Scholar
36. • Ioannou G.
    • Bryson C.
    • Weiss N.
    • et al.
    The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection.
    Hepatology. 2013; 57: 249-257
    View in Article

    • Google Scholar
37. • Reddy K.R.
    • Beavers K.L.
    • Hammond S.P.
    • et al.
    American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
    Gastroenterology. 2015; 148: 215-219
    View in Article

    • Google Scholar
38. • Myint A.
    • Tong M.J.
    • Beaven S.W.
    Reactivation of hepatitis B virus: a review of clinical guidelines.
    Clin Liver Dis. 2020; 15: 162-167
    View in Article

    • Google Scholar
39. • Su J.
    • Lim J.K.
    Hepatitis B virus reactivation in the setting of immunosuppressive drug therapy.
    Gastroenterol Hepatol. 2019; 15: 585-592
    View in Article

    • Google Scholar
40. • Lau G.K.K.
    • Yiu H.H.Y.
    • Fong D.Y.T.
    • et al.
    Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.
    Gastroenterology. 2003; 125: 1742-1749
    View in Article

    • Google Scholar
41. • Huang Y.H.
    • Hsiao L.T.
    • Hong Y.C.
    • et al.
    Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    J Clin Oncol. 2013; 31: 2765-2772
    View in Article

    • Google Scholar
42. • Papatheodoridis G.V.
    • Lekakis V.
    • Voulgaris T.
    • et al.
    Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion.
    J Hepatol. 2022; 77: 1670-1689
    View in Article

    • Google Scholar
43. • Hwang J.P.
    • Feld J.J.
    • Hammond S.P.
    • et al.
    Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update.
    J Clin Oncol. 2020; 38: 3698-3715
    View in Article

    • Google Scholar
44. • Kwak Y.E.
    • Stein S.M.
    • Lim J.K.
    Practice patterns in hepatitis B virus screening before cancer chemotherapy in a major US hospital network.
    Dig Dis Sci. 2018; 63: 61-71
    View in Article

    • Google Scholar